10 años de medicina de precisión - page 32

Key Questions: THE BEST FIRST LINE (I)

•

The monoclonal antibodies shown to improve of clinical outcome when

combined with polichemotherapy in the first line setting (EVIDENCE LEVEL IB)

Cmab-QT

Bv-QT

ORR (ITT)

62,0%

58,0%

ORR

72,2%

63,1%

PFS

10,0 m

10,3 m

OS KRASwt 28,7 m

25.0 m

OS RASwt

33,1 m

25.0 m

P=.18

P=.017

P=.55

P=.017

P=.005

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,22,23,24,25,26,27,28,29,30,31 33,34,35,36,37,38,39,40,41,42,...45